Browsing by author "Larkin, James"
Now showing items 41-60 of 74
-
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected <i>BRAF</i> V600-Mutant Stage III Melanoma.
Hauschild, A; Dummer, R; Schadendorf, D; Santinami, M; Atkinson, V; et al. (2018-12)Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600-mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov ... -
Malignant Melanoma of the Gastrointestinal Tract: Symptoms, Diagnosis, and Current Treatment Options.
Kohoutova, D; Worku, D; Aziz, H; Teare, J; Weir, J; et al. (MDPI, 2021-02-05)Malignant melanoma (MM) has become the fifth most frequent cancer in the UK. It is the most common carcinoma to metastasize to the gastrointestinal (GI) tract. MM particularly has an affinity to spread to the small bowel, ... -
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆.
Tarhini, AA; Toor, K; Chan, K; McDermott, DF; Mohr, P; et al. (ELSEVIER, 2021-02-06)BACKGROUND: Approved first-line treatments for patients with BRAF V600-mutant advanced melanoma include nivolumab (a programmed cell death protein 1 inhibitor) plus ipilimumab (a cytotoxic T lymphocyte antigen-4 inhibitor; ... -
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba, E; Le Teuff, G; Eisen, T; Stewart, GD; Fife, K; et al. (2017-07)Background Treatment of non-clear cell renal cell carcinoma (RCC) remains controversial despite several recent prospective studies of targeted therapies (TT). Often Vascular Endothelial growth Factor (VEGF) and Mammalian ... -
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
Ascierto, PA; Lipson, EJ; Dummer, R; Larkin, J; Long, GV; et al. (American Society of Clinical Oncology (ASCO), 2023-02-13)PURPOSE: Nivolumab and relatlimab activity in advanced melanoma with prior progression on anti-programmed death-1/programmed death ligand 1 (PD-(L)1)-containing regimens is under investigation. RELATIVITY-047 demonstrated ... -
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
McDermott, DF; Lee, J-L; Bjarnason, GA; Larkin, JMG; Gafanov, RA; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2021-03-20)PURPOSE: Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent ... -
Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries.
Giles, R; Maskens, D; Bick, R; Martinez, R; Packer, M; et al. (ELSEVIER, 2022-03-01)The International Kidney Cancer Coalition (IKCC) is a federation of 46 affiliated patient organisations representing 1.2 million patients worldwide that is committed to reducing the global burden of kidney cancer. A ... -
Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.
Yip, K; Melcher, A; Harrington, K; Illidge, T; Nobes, J; et al. (2018-04) -
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
Rasco, DW; Medina, T; Corrie, P; Pavlick, AC; Middleton, MR; et al. (SPRINGER, 2023-07-01)PURPOSE: Genomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors. Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan‑RAF inhibitor. ... -
A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma.
Bauer, S; Larkin, J; Hodi, FS; Stephen, F; Kapiteijn, EHW; et al. (FRONTIERS MEDIA SA, 2023-06-09)BACKGROUND: Uveal melanoma is a disease characterized by constitutive activation of the G alpha pathway and downstream signaling of protein kinase C (PKC) and the mitogen-activated protein kinase (MAPK) pathway. While ... -
Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui, MS; Lai, ZM; Spain, L; Greener, V; Turajlic, S; et al. (SPRINGER, 2020-05-24)PURPOSE: Ipilimumab, a monoclonal antibody inhibiting CLTA-4, is an established treatment in metastatic melanoma, either alone or in combination with nivolumab, and results in immune mediated adverse events, including ... -
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.
Buckley, HL; Collinson, FJ; Ainsworth, G; Poad, H; Flanagan, L; et al. (2019-11-14)BACKGROUND:The combination of nivolumab, a programmed death-1 (PD-1) targeted monoclonal antibody, with the cytotoxic T-lymphocyte antigen-4 (CTLA-4) targeted antibody, ipilimumab, represents a new standard of care in the ... -
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Kennedy, OJ; Kicinski, M; Valpione, S; Gandini, S; Suciu, S; et al. (ELSEVIER SCI LTD, 2022-04-01)BACKGROUND: β-adrenergic receptors are upregulated in melanoma cells and contribute to an immunosuppressive, pro-tumorigenic microenvironment. This study investigated the prognostic and predictive value of β-adrenoreceptor ... -
Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib.
Seifert, H; Fisher, R; Martin-Liberal, J; Edmonds, K; Hughes, P; et al. (2016-04)The BRAF inhibitor vemurafenib is an effective drug in patients with BRAF mutant metastatic melanoma, but resistance occurs after a median of 6 months. The anti-CTLA4-antibody, ipilimumab, is a standard first-line and ... -
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
Rini, BI; Moslehi, JJ; Bonaca, M; Schmidinger, M; Albiges, L; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2022-06-10)PURPOSE: Both immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for advanced renal cell carcinoma treatment and can cause cardiovascular events (CVs); thus, ... -
Prospective cohort study of ultrasound surveillance of regional lymph nodes in patients with intermediate-risk cutaneous melanoma.
Hayes, AJ; Moskovic, E; O'Meara, K; Smith, HG; Pope, RJE; et al. (WILEY, 2019-05-01)BACKGROUND: For patients with intermediate-thickness melanoma, surveillance of regional lymph node basins by clinical examination alone has been reported to result in a larger number of lymph nodes involved by melanoma ... -
Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma.
Homicsko, K; Dummer, R; Hoeller, C; Wolchok, JD; Hodi, FS; et al. (MDPI, 2022-05-05)The impact of proton pump inhibitors (PPIs) on clinical outcomes with first-line immune checkpoint inhibitors (ICIs) in patients with metastatic melanoma was previously analyzed in the phase II study, CheckMate 069. This ... -
RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.
Meade, A; Oza, B; Frangou, E; Smith, B; Bryant, H; et al. (ELSEVIER SCIENCE INC, 2021-09-16)The development of therapeutics in oncology is a highly active research area for the pharmaceutical and biotechnology industries, but also has a strong academic base. Many new agents have been developed in recent years, ... -
RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
Oza, B; Frangou, E; Smith, B; Bryant, H; Kaplan, R; et al. (ELSEVIER SCIENCE INC, 2021-09-16)BACKGROUND: 20-60% of patients with initially locally advanced Renal Cell Carcinoma (RCC) develop metastatic disease despite optimal surgical excision. Adjuvant strategies have been tested in RCC including cytokines, ... -
Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk Score.
Schmidinger, M; Porta, C; Oudard, S; Denechere, G; Brault, Y; et al. (CIG MEDIA GROUP, LP, 2020-10-01)BACKGROUND: ADONIS is an ongoing observational study in 9 European countries, designed to evaluate treatment patterns/outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with first-line sunitinib and/or ...